We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
ISU’s vaccine is “intended to address some of the limitations of the vaccines currently in development by targeting room temperature storage and single-dose nasal self-administration as key capabilities,” Zeteo said. Read More
Sputnik V will be “two or more times cheaper than foreign vaccines based on mRNA technology with similar efficacy rates,” Russia’s sovereign wealth fund said. Read More
Merck is expanding further into the biotech sector by acquiring Rockville, Md., biopharma company OncoImmune for $425 million, netting in the process an investigational drug that has shown promise as a treatment for hospitalized COVID-19 patients. Read More
UK regulators are reviewing the latest data on the Pfizer/BioNTech COVID-19 vaccine candidate and aim to decide on an approval “in the shortest time possible, without compromising the thoroughness of our review,” the agency’s top official said yesterday. Read More
Regeneron has won Emergency Use Authorization (EUA) from the FDA for its investigational antibody cocktail for the treatment of patients with mild-to-moderate COVID-19 symptoms at high risk of severe disease progression or hospitalization — and an initial 30,000 doses are expected to ship today. Read More
AstraZeneca’s (AZ) and the University of Oxford’s COVID-19 vaccine candidate — which has been shown to be 90 percent effective at a one-and-a-half-dose level — could be a godsend for low- and middle-income nations due to its relative ease of distribution, high manufacturing capacity and the not-for-profit price the drugmaker has vowed to offer developing countries “in perpetuity.” Read More
European Commission President Ursula von der Leyen urged the G20 leaders to commit to providing $4.5 billion for the World Health Organization’s Access to COVID Tools (ACT) Accelerator program. Read More
The FDA has granted an Emergency Use Authorization (EUA) for Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) in combination with Gilead Sciences’ antiviral Veklury (remdesivir) for treatment of COVID-19 patients needing supplemental oxygen. Read More
The World Health Organization (WHO) released revised guidance on Gilead Sciences’ antiviral Veklury (remdesivir) after an expert panel review of multiple trials found no evidence for the drug’s effectiveness in treating COVID-19. Read More
As the countdown begins toward an eagerly anticipated FDA authorization for Pfizer’s COVID-19 vaccine candidate, an advisory committee of the Centers for Disease Control and Prevention (CDC) is meeting today to discuss the phased distribution of coronavirus vaccines. Read More
Russia’s Gamaleya Research Institute has reportedly resumed dosing in a phase 3 trial evaluating its COVID-19 vaccine, Sputnik V., but a Russian government spokesperson denies that the study was ever paused. Read More